374 related articles for article (PubMed ID: 16399572)
21. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy.
Hui CK; Cheung WW; Au WY; Lie AK; Zhang HY; Yueng YH; Wong BC; Leung N; Kwong YL; Liang R; Lau GK
Gut; 2005 Nov; 54(11):1597-603. PubMed ID: 16000641
[TBL] [Abstract][Full Text] [Related]
22. High risk of hepatitis B-virus reactivation after hematopoietic cell transplantation in hepatitis B core antibody-positive patients.
Matsue K; Aoki T; Odawara J; Fujiwara H; Iwama K; Kimura S; Yamakura M; Takeuch M
Eur J Haematol; 2009 Oct; 83(4):357-64. PubMed ID: 19508685
[TBL] [Abstract][Full Text] [Related]
23. Role of long-term lamivudine treatment of hepatitis B virus recurrence after liver transplantation.
Woo HY; Choi JY; Jang JW; You CR; Bae SH; Yoon SK; Yang JM; Choi SW; Han NI; Kim DG
J Med Virol; 2008 Nov; 80(11):1891-9. PubMed ID: 18814257
[TBL] [Abstract][Full Text] [Related]
24. The difficulties of managing severe hepatitis B virus reactivation.
Roche B; Samuel D
Liver Int; 2011 Jan; 31 Suppl 1():104-10. PubMed ID: 21205146
[TBL] [Abstract][Full Text] [Related]
25. [Hepatitis B virus reactivation in patients with HBs antibodies after allogeneic hematopoietic stem cell transplantation].
Fujimaki K; Nakaseko C; Oshima K; Sakai M; Chou R; Kanda Y; Nishimura M; Kanamori H; Sakamaki H
Rinsho Ketsueki; 2007 May; 48(5):386-90. PubMed ID: 17571583
[TBL] [Abstract][Full Text] [Related]
26. No hepatitis recurrence using combination prophylaxis in HBV-positive liver transplant recipients with YMDD mutants.
Caccamo L; Romeo R; Rossi G; Maggioni M; Radice F; Lunghi G; Colombo M; Fassati LR
Transpl Int; 2005 Feb; 18(2):186-92. PubMed ID: 15691271
[TBL] [Abstract][Full Text] [Related]
27. Outcome of lamivudine resistant hepatitis B virus mutant post-liver transplantation on lamivudine monoprophylaxis.
Chan HL; Chui AK; Lau WY; Chan FK; Hui AY; Rao AR; Wong J; Lai EC; Sung JJ
Clin Transplant; 2004 Jun; 18(3):295-300. PubMed ID: 15142051
[TBL] [Abstract][Full Text] [Related]
28. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration.
Dai MS; Wu PF; Shyu RY; Lu JJ; Chao TY
Liver Int; 2004 Dec; 24(6):540-6. PubMed ID: 15566502
[TBL] [Abstract][Full Text] [Related]
29. The incidence and clinical outcome of YMDD mutants in hepatitis B surface antigen-positive renal allograft recipients after prolonged lamivudine therapy.
Gwak GY; Huh W; Lee DH; Choi MS; Lee JH; Koh KC; Kim SJ; Joh JW; Oh HY
Transplant Proc; 2007 Dec; 39(10):3121-6. PubMed ID: 18089336
[TBL] [Abstract][Full Text] [Related]
30. Lamivudine prophylaxis and treatment of hepatitis B Virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab.
Moses SE; Lim ZY; Sudhanva M; Devereux S; Ho AY; Pagliuca A; Zuckerman M; Mufti GJ
J Med Virol; 2006 Dec; 78(12):1560-3. PubMed ID: 17063522
[TBL] [Abstract][Full Text] [Related]
31. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation.
Lau GK; He ML; Fong DY; Bartholomeusz A; Au WY; Lie AK; Locarnini S; Liang R
Hepatology; 2002 Sep; 36(3):702-9. PubMed ID: 12198664
[TBL] [Abstract][Full Text] [Related]
32. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients.
Benhamou Y; Fleury H; Trimoulet P; Pellegrin I; Urbinelli R; Katlama C; Rozenbaum W; Le Teuff G; Trylesinski A; Piketty C;
Hepatology; 2006 Mar; 43(3):548-55. PubMed ID: 16496322
[TBL] [Abstract][Full Text] [Related]
33. The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma.
He YF; Li YH; Wang FH; Jiang WQ; Xu RH; Sun XF; Xia ZJ; Huang HQ; Lin TY; Zhang L; Bao SP; He YJ; Guan ZZ
Ann Hematol; 2008 Jun; 87(6):481-5. PubMed ID: 18299831
[TBL] [Abstract][Full Text] [Related]
34. Reactivation of resolved hepatitis B virus infection after allogeneic haematopoietic stem cell transplantation.
Knöll A; Boehm S; Hahn J; Holler E; Jilg W
Bone Marrow Transplant; 2004 May; 33(9):925-9. PubMed ID: 15004543
[TBL] [Abstract][Full Text] [Related]
35. Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection.
Ahmed A; Keeffe EB
Am J Gastroenterol; 1999 Jan; 94(1):249-51. PubMed ID: 9934765
[TBL] [Abstract][Full Text] [Related]
36. Hepatitis B virus infection: pathogenesis, reactivation and management in hematopoietic stem cell transplant recipients.
Moses SE; Lim Z; Zuckerman MA
Expert Rev Anti Infect Ther; 2011 Oct; 9(10):891-9. PubMed ID: 21973301
[TBL] [Abstract][Full Text] [Related]
37. Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor.
Cerva C; Colagrossi L; Maffongelli G; Salpini R; Di Carlo D; Malagnino V; Battisti A; Ricciardi A; Pollicita M; Bianchi A; Picardi A; Cudillo L; Cerretti R; De Angelis G; Cantonetti M; Andreoni M; Perno CF; Arcese W; Svicher V; Sarmati L
Clin Microbiol Infect; 2016 Nov; 22(11):946.e1-946.e8. PubMed ID: 27475741
[TBL] [Abstract][Full Text] [Related]
38. Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy.
Kazim SN; Chauhan R; Das BC; Sarin SK
J Gastroenterol Hepatol; 2006 Oct; 21(10):1525-32. PubMed ID: 16928212
[TBL] [Abstract][Full Text] [Related]
39. Evolution of multi-drug resistant hepatitis B virus during sequential therapy.
Yim HJ; Hussain M; Liu Y; Wong SN; Fung SK; Lok AS
Hepatology; 2006 Sep; 44(3):703-12. PubMed ID: 16941700
[TBL] [Abstract][Full Text] [Related]
40. [Correlation of HBV DNA level and viral breakthrough during lamivudine therapy for chronic hepatitis B].
Park HS; Lee DH; Heo J; Kim GH; Kang DH; Song GA; Cho M
Korean J Hepatol; 2006 Jun; 12(2):173-83. PubMed ID: 16804342
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
